Technology platform for ultrasensitive diagnostics

The first technology platform that can measure levels of bioavailable copper with high precision.
Direct measurement of free copper in serum or plasma has the potential to provide a unique tool for the screening, diagnosis, and monitoring of diseases e.g. Alzheimers disease(AD), Menkes and Wilsons Disease.

GUV Contact: Helena Lundquist